Back to Search Start Over

Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals.

Authors :
Nevado J
García-Miñaúr S
Palomares-Bralo M
Vallespín E
Guillén-Navarro E
Rosell J
Bel-Fenellós C
Mori MÁ
Milá M
Del Campo M
Barrúz P
Santos-Simarro F
Obregón G
Orellana C
Pachajoa H
Tenorio JA
Galán E
Cigudosa JC
Moresco A
Saleme C
Castillo S
Gabau E
Pérez-Jurado L
Barcia A
Martín MS
Mansilla E
Vallcorba I
García-Murillo P
Cammarata-Scalisi F
Gonçalves Pereira N
Blanco-Lago R
Serrano M
Ortigoza-Escobar JD
Gener B
Seidel VA
Tirado P
Lapunzina P
Source :
Frontiers in genetics [Front Genet] 2022 Apr 12; Vol. 13, pp. 652454. Date of Electronic Publication: 2022 Apr 12 (Print Publication: 2022).
Publication Year :
2022

Abstract

Phelan-McDermid syndrome (PMS, OMIM# 606232) results from either different rearrangements at the distal region of the long arm of chromosome 22 (22q13.3) or pathogenic sequence variants in the SHANK3 gene. SHANK3 codes for a structural protein that plays a central role in the formation of the postsynaptic terminals and the maintenance of synaptic structures. Clinically, patients with PMS often present with global developmental delay, absent or severely delayed speech, neonatal hypotonia, minor dysmorphic features, and autism spectrum disorders (ASD), among other findings. Here, we describe a cohort of 210 patients with genetically confirmed PMS. We observed multiple variant types, including a significant number of small deletions (<0.5 Mb, 64/189) and SHANK3 sequence variants (21 cases). We also detected multiple types of rearrangements among microdeletion cases, including a significant number with post-zygotic mosaicism (9.0%, 17/189), ring chromosome 22 (10.6%, 20/189), unbalanced translocations ( de novo or inherited, 6.4%), and additional rearrangements at 22q13 (6.3%, 12/189) as well as other copy number variations in other chromosomes, unrelated to 22q deletions (14.8%, 28/189). We compared the clinical and genetic characteristics among patients with different sizes of deletions and with SHANK3 variants . Our findings suggest that SHANK3 plays an important role in this syndrome but is probably not uniquely responsible for all the spectrum features in PMS. We emphasize that only an adequate combination of different molecular and cytogenetic approaches allows an accurate genetic diagnosis in PMS patients. Thus, a diagnostic algorithm is proposed.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Nevado, García-Miñaúr, Palomares-Bralo, Vallespín, Guillén-Navarro, Rosell, Bel-Fenellós, Mori, Milá, Campo, Barrúz, Santos-Simarro, Obregón, Orellana, Pachajoa, Tenorio, Galán, Cigudosa, Moresco, Saleme, Castillo, Gabau, Pérez-Jurado, Barcia, Martín, Mansilla, Vallcorba, García-Murillo, Cammarata-Scalisi, Gonçalves Pereira, Blanco-Lago, Serrano, Ortigoza-Escobar, Gener, Seidel, Tirado, Lapunzina and Spanish PMS Working Group.)

Details

Language :
English
ISSN :
1664-8021
Volume :
13
Database :
MEDLINE
Journal :
Frontiers in genetics
Publication Type :
Academic Journal
Accession number :
35495150
Full Text :
https://doi.org/10.3389/fgene.2022.652454